MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

133.21 +2.35 (+1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,202,063
Open 132.10
Bid (Size) 132.50 (200)
Ask (Size) 133.50 (100)
Prev. Close 130.86
Today's Range 130.59 - 134.09
52wk Range 108.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside. 
Via The Motley Fool
Topics ETFs
News headline image
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q2 CY2026, with sales up 10.2% year on year to $7.80 billio... 
Via StockStory

Performance

YTD
+9.5%
+9.5%
1 Month
-1.9%
-1.9%
3 Month
+1.4%
+1.4%
6 Month
-12.6%
-12.6%
1 Year
+20.8%
+20.8%

More News

Read More
News headline image
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance ↗
Via Chartmill
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
Gilead Sciences Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Via StockStory
News headline image
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up ↗
Via Investor's Business Daily
News headline image
SpaceX Could Swing $204 Billion After Earnings ↗
Via Benzinga
News headline image
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity ↗
Via MarketBeat
News headline image
Compugen Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗
Via Benzinga
News headline image
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence
News headline image
2 Large-Cap Stocks for Long-Term Investors and 1 Facing Challenges
Via StockStory
News headline image
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial ↗
Via Benzinga
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
Via The Motley Fool
Topics ETFs
News headline image
Global Prophylactic HIV Drug Market Growing at 7.8% CAGR Through 2034 ↗
Via Talk Markets
News headline image
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
Via The Motley Fool
Topics ETFs
News headline image
Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill ↗
Via Benzinga
News headline image
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Market-Beating Stocks with Solid Fundamentals
Via StockStory
Topics Energy

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 133.21
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 08/07/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 167.02B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 167B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story